Target Name: RNF149
NCBI ID: G284996
Review Report on RNF149 Target / Biomarker Content of Review Report on RNF149 Target / Biomarker
RNF149
Other Name(s): Ring finger protein 149 | RN149_HUMAN | ring finger protein 149 | DNA polymerase-transactivated protein 2 | E3 ubiquitin-protein ligase RNF149 | RING-type E3 ubiquitin transferase RNF149 | DNAPTP2 | RING finger protein 149

Targeting RFP149 with Small Nucleotides

Ring finger protein 149 (RNF149) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a member of the superfamily of RNA-protein interactions and is involved in various cellular processes. One of the unique features of RFP149 is its ability to interact with small molecules, including small nucleotides, such as uracils and thymidine. This interaction between RFP149 and small nucleotides makes it an attractive target for drug development.

Drug Development

RFP149 has been identified as a potential drug target due to its involvement in various cellular processes that are crucial for human health. One of the key targets of RFP149 is its interaction with small nucleotides, which are important regulators of gene expression and cell signaling. By interacting with these small nucleotides, RFP149 plays a role in the regulation of cellular processes that are essential for human health, such as cell growth, apoptosis, and inflammation.

In addition to its role in cellular signaling, RFP149 has also been shown to play a key role in the development and progression of various diseases, including cancer. Studies have shown that RFP149 is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. This overexpression is associated with poor prognosis and increased cancer progression.

Anti-cancer Potential

Given the potential role of RFP149 in cancer development, researchers have been actively exploring the use of small nucleotides as therapeutic agents to target this protein. One of the most promising strategies is the use of small nucleotides that can bind to specific regions of RFP149. These small nucleotides can then act as inhibitors of RFP149 function, leading to a reduction in cancer cell proliferation.

One of the most promising small nucleotides used to target RFP149 is uracil. Uracil is a natural compound that has been shown to interact with various proteins, including RFP149. When uracil binds to RFP149, it inhibits the activity of this protein and leads to a reduction in cancer cell proliferation.

Another small nucleotide that has been shown to be effective in targeting RFP149 is thymidine. Thymidine is a natural compound that is involved in the regulation of DNA replication and cell growth. When thymidine binds to RFP149, it inhibits the activity of this protein and leads to a reduction in cancer cell proliferation.

In addition to small nucleotides, researchers have also explored the use of small molecules that can bind to specific regions of RFP149. These small molecules can act as inhibitors of RFP149 function and lead to a reduction in cancer cell proliferation.

Despite the promising potential of small nucleotides as therapeutic agents, there are also potential drawbacks to their use. One of the main challenges is the difficulty in predicting the binding interactions of small nucleotides with RFP149. This is because the binding interactions of these small nucleotides with RFP149 are complex and can be difficult to predict.

Conclusion

Ring finger protein 149 (RFP149) is a protein that is involved in various cellular processes and has been identified as a potential drug target due to its interaction with small nucleotides. The use of small nucleotides, such as uracil and thymidine, has been shown to be effective in inhibiting RFP149 function and leading to a reduction in cancer cell proliferation. Further research is needed to fully understand the potential of these small nucleotides as therapeutic agents and to develop safe and effective treatments for cancer.

Protein Name: Ring Finger Protein 149

Functions: E3 ubiquitin-protein ligase. Ubiquitinates BRAF, inducing its proteasomal degradation

The "RNF149 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNF149 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RNF150 | RNF151 | RNF152 | RNF157 | RNF157-AS1 | RNF165 | RNF166 | RNF167 | RNF168 | RNF169 | RNF17 | RNF170 | RNF175 | RNF180 | RNF181 | RNF182 | RNF183 | RNF185 | RNF186 | RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44 | RNF5 | RNF5P1 | RNF6 | RNF7 | RNF7P1 | RNF8 | RNFT1 | RNFT2 | RNGTT | RNH1 | RNLS | RNMT | RNPC3 | RNPC3-DT | RNPEP | RNPEPL1 | RNPS1 | RNPS1P1 | RNR1 | RNR2 | RNU1-1 | RNU1-100P | RNU1-108P | RNU1-11P | RNU1-134P | RNU1-18P | RNU1-3 | RNU1-31P | RNU1-32P | RNU1-36P | RNU1-38P | RNU1-4 | RNU1-42P | RNU1-55P | RNU1-61P | RNU1-63P | RNU1-72P | RNU1-73P | RNU1-78P | RNU1-7P | RNU1-82P | RNU1-88P | RNU105B | RNU11